Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their primary endpoint Read more
Lilly’s orforglipron and other key catalysts can reshape drug landscape in Q3 2025: GlobalData Read more
Sun Pharma and Moebius Medical publish clinical and mechanistic data on non-opioid knee osteoarthritis treatment MM-II Read more